# Glycomine funding rounds and investors

As of 14 Oct 2026, Glycomine has raised $115M across 1 verified round on record; latest: $115 million Series C led by abrdn, Advent Life Sciences and 1 other, announced 16 Apr 2025.

Glycomine develops replacement therapies for rare genetic diseases, particularly focusing on PMM2-CDG treatments.

Website: https://glycomine.com  
Headquarters: San Carlos, California  
Page: https://fireround.dev/companies/glycomine.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-04-16 | Series C | $115 million | abrdn, Advent Life Sciences, CTI Life Sciences Fund | Abingworth, Asahi Kasei Ventures, Chiesi Ventures, Novo Holdings, Remiges Ventures, RiverVest Venture Partners, Sanderling Ventures, Sanofi Ventures | [glycomine.com](https://www.glycomine.com/glycomine-announces-115-million-series-c-financing-to-advance-lead-drug-candidate-glm101-into-a-phase-2b-clinical-trial-for-pmm2-cdg), [businesswire.com](https://www.businesswire.com/news/home/20250416688920/en/Glycomine-Announces-%24115-Million-Series-C-Financing-to-Advance-Lead-Drug-Candidate-GLM101-into-a-Phase-2b-Clinical-Trial-for-PMM2-CDG) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.